UY30450A1 - Aplicacinn de alta frecuencia de terapia con toxina botulenica - Google Patents

Aplicacinn de alta frecuencia de terapia con toxina botulenica

Info

Publication number
UY30450A1
UY30450A1 UY30450A UY30450A UY30450A1 UY 30450 A1 UY30450 A1 UY 30450A1 UY 30450 A UY30450 A UY 30450A UY 30450 A UY30450 A UY 30450A UY 30450 A1 UY30450 A1 UY 30450A1
Authority
UY
Uruguay
Prior art keywords
botulen
toxin
high frequency
frequency therapy
therapy application
Prior art date
Application number
UY30450A
Other languages
English (en)
Spanish (es)
Inventor
Dirk Dressler
Reiner Benecke
Matthias Marx
Susanne Grafe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38462381&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30450(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY30450A1 publication Critical patent/UY30450A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY30450A 2006-06-29 2007-06-28 Aplicacinn de alta frecuencia de terapia con toxina botulenica UY30450A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81775606P 2006-06-29 2006-06-29

Publications (1)

Publication Number Publication Date
UY30450A1 true UY30450A1 (es) 2009-04-30

Family

ID=38462381

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30450A UY30450A1 (es) 2006-06-29 2007-06-28 Aplicacinn de alta frecuencia de terapia con toxina botulenica

Country Status (17)

Country Link
US (3) US8557255B2 (https=)
EP (2) EP2484373A1 (https=)
JP (2) JP5897784B2 (https=)
KR (3) KR20150126979A (https=)
CN (1) CN101460190A (https=)
AR (1) AR061669A1 (https=)
AU (1) AU2007264008B2 (https=)
BR (1) BRPI0713061A2 (https=)
CA (1) CA2654214C (https=)
CL (1) CL2007001911A1 (https=)
IL (1) IL195201A (https=)
MX (1) MX2009000253A (https=)
RU (1) RU2453333C2 (https=)
TW (1) TWI519310B (https=)
UY (1) UY30450A1 (https=)
WO (1) WO2008000490A1 (https=)
ZA (1) ZA200808491B (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
US10792344B2 (en) * 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
CA2686642A1 (en) * 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
US7473429B1 (en) * 2007-07-27 2009-01-06 Renfroe J Ben Method for treatment of laminitis in animals
US8455459B2 (en) 2007-08-02 2013-06-04 Medicis Pharmaceutical Corporation Method of applying an injectable filler
US20090204101A1 (en) * 2007-08-20 2009-08-13 Wortzman Mitchell S Method of applying an injectable filler
US9161970B2 (en) 2007-12-12 2015-10-20 Allergan, Inc. Dermal filler
US9044477B2 (en) * 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
EP2072039A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects
EP2072057A1 (en) 2007-12-21 2009-06-24 Merz Pharma GmbH & Co.KGaA Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury
WO2009123174A1 (ja) * 2008-03-31 2009-10-08 財団法人化学及血清療法研究所 A2型ボツリヌス神経毒素製剤
EP2337790B1 (en) 2008-08-29 2016-07-13 Merz Pharma GmbH & Co. KGaA Clostridial neurotoxins with altered persistency
ES2426667T3 (es) 2008-09-09 2013-10-24 Susanne Grafe Toxina botulínica para introducir infertilidad temporal en un vertebrado (por ejemplo, un ser humano)
EP2248518B1 (en) * 2009-04-17 2013-01-16 Merz Pharma GmbH & Co. KGaA Formulation for stabilizing proteins, peptides or mixtures thereof.
EP2246065A1 (en) 2009-04-29 2010-11-03 Merz Pharma GmbH & Co. KGaA Intrastriatal botulinum toxin therapy
WO2011023213A1 (en) * 2009-08-28 2011-03-03 Merz Pharma Gmbh & Co. Kgaa Modified chemodenervating agents
PH12012500549A1 (en) * 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
KR101134146B1 (ko) 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
EP2399601A1 (en) 2010-06-24 2011-12-28 Merz Pharma GmbH & Co. KGaA Botulinum toxin therapy
JP5990176B2 (ja) 2010-10-12 2016-09-07 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン タンパク質の安定化に好適な哺乳動物性賦形剤非含有製剤
RU2454170C1 (ru) * 2011-02-21 2012-06-27 Федеральное государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения и социального развития Российской Федерации Способ лечения спастичности мышц у больных с позвоночно-спинномозговой травмой
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
RU2535115C1 (ru) 2013-05-15 2014-12-10 Бости Трейдинг Лтд Фармацевтический состав, содержащий нейротоксин ботулина
KR102272580B1 (ko) * 2013-07-30 2021-07-05 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도
WO2015039206A1 (en) * 2013-09-20 2015-03-26 Mddt Inc. Diagnosing and treating movement disorders
US10231665B2 (en) 2013-09-20 2019-03-19 Mddt Inc. Diagnosing and treating movement disorders
US20170128551A1 (en) * 2014-06-13 2017-05-11 Klaus Fink Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US20170112907A1 (en) * 2014-06-13 2017-04-27 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US20180140685A1 (en) * 2015-04-24 2018-05-24 Consiglio Nazionale Delle Ricerche A new therapeutic use of the botulinum neurotoxin serotype a
US11602303B2 (en) * 2017-02-10 2023-03-14 Mauricio De Maio Domingos Methods and systems for preventing, correcting, transforming, and modifying facial, aesthetics, and consulting patients regarding the same
MX2021009922A (es) * 2019-02-21 2021-09-14 Merz Pharma Gmbh & Co Kgaa Usos novedosos de neurotoxina botulinica para el tratamiento del temblor.
RU2721300C2 (ru) * 2019-10-17 2020-05-18 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ лечения нейрогенной дисфункции мочевого пузыря, проявляющейся функциональной инфравезикальной обструкцией у женщин
US11090371B1 (en) 2019-10-18 2021-08-17 Penland Foundation Treatment of cirrhosis using botulinum toxin
US10960061B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of amyotrophic lateral sclerosis using botulinum toxin
US10973873B1 (en) 2019-10-18 2021-04-13 Penland Foundation Treatment of asthma using botulinum toxin
US11925677B2 (en) 2021-07-12 2024-03-12 Penland Foundation Treatment of diabetes and chronic pancreatitis using botulinum toxin
KR102520631B1 (ko) 2019-10-18 2023-04-12 펜랜드 파운데이션 치료에 사용하기 위한 보톨리늄 독소
US11241479B2 (en) 2019-10-18 2022-02-08 Penland Foundation Treatment methods using botulinum toxins
US10987411B1 (en) 2019-10-18 2021-04-27 Penland Foundation Treatment of chronic obstructive pulmonary disease using botulinum toxin
WO2021231666A1 (en) 2020-05-15 2021-11-18 Penland Foundation Treatment of asthma using botulinum toxin
US10960060B1 (en) 2019-10-18 2021-03-30 Penland Foundation Treatment of cardiac arrhythmia using botulinum toxin
US10967052B1 (en) 2019-10-18 2021-04-06 Penland Foundation Treatment of dyslexia using botulinum toxin
WO2021137667A1 (ko) * 2019-12-30 2021-07-08 주식회사 에이티지씨 보툴리눔 신경독소를 포함하는 파킨슨병 치료용 조성물 및 이를 이용한 파킨슨병 치료 방법
WO2023287729A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of acute and chronic kidney disease
USD1108809S1 (en) * 2023-08-21 2026-01-13 Taizhou Info Plastic Mould Co., Ltd. Storage box

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3888977A (en) * 1973-02-01 1975-06-10 Murray J Sanders Modified neurotoxin
US4932936A (en) * 1988-01-29 1990-06-12 Regents Of The University Of Minnesota Method and device for pharmacological control of spasticity
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
GB9120306D0 (en) * 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
EP1099445A3 (en) * 1993-06-10 2001-09-05 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US7037680B2 (en) * 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
ES2332905T3 (es) * 1993-12-28 2010-02-15 Allergan, Inc. Uso del componente neurotoxico de la toxina botulinica para el tratamiento de trastornos de musculos lisos.
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
US8187612B2 (en) * 1993-12-28 2012-05-29 Allergan, Inc. Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
EP1011695B2 (en) * 1997-07-15 2009-11-04 The Regents of the University of Colorado Use of neurotoxin therapy for treatment of prostate disorders
DE69930831T2 (de) * 1998-07-07 2006-11-30 Sun Chemical Corp. Kationisch härtbare lithographische druckfaben mit einem geringen gehalt an fl üchtigen organischen verbindungen
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
DE69943220D1 (de) 1998-09-11 2011-04-07 Gr Intellectual Reserve Llc Verfahren und system für biometrische erkennung basiert auf elektrischen und/oder magnetischen eigenschaften
DE19856897A1 (de) * 1998-12-10 2000-06-15 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum zur Unterdrückung von Schnarchgeräuschen
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6348434B1 (en) * 1999-07-01 2002-02-19 Basf Aktiengesellschaft Herbicidal emulsifiable concentrate
US20030180289A1 (en) * 1999-09-23 2003-09-25 Foster Keith Alan Inhibition of secretion from non-neuronal cells
JP2003512603A (ja) 1999-10-05 2003-04-02 テクノロジィ ファイナンス コーポレイション（プロプライエタリー） リミテッド 回転軸におけるトルクによるねじれの測定
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
WO2001026738A1 (en) 1999-10-14 2001-04-19 Rose Manufacturing Company Lanyard with integral fall arrest energy absorber
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US20030219462A1 (en) * 2000-07-21 2003-11-27 Allergan Sales, Inc Clostridial neurotoxin compositions and modified clostridial neurotoxins
DE10043982A1 (de) * 2000-09-05 2002-03-14 Armin Maurer Verfahren zur Verbesserung des Haarwuchses menschlichen Kopfhaares
US20020086036A1 (en) * 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US7226605B2 (en) * 2001-07-27 2007-06-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Botulinum toxin in the treatment or prevention of acne
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US20050106183A1 (en) * 2002-01-31 2005-05-19 Lamb Gregory B. Method of treating pain
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US7140371B2 (en) * 2002-03-14 2006-11-28 Allergan, Inc. Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins
US7300412B2 (en) * 2002-05-10 2007-11-27 Hospital For Joint Diseases Methods for therapeutic treatment of carpal tunnel syndrome
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
WO2003101483A1 (en) * 2002-05-31 2003-12-11 Solux Corporation Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
AU2003227362A1 (en) 2002-08-06 2004-03-03 Genox Research, Inc. Method of examining atopic dermatitis
US7824693B2 (en) * 2002-08-19 2010-11-02 Ira Sanders Treatment of fine wrinkles with clostridia neurotoxins
US7288259B2 (en) * 2002-08-19 2007-10-30 Ira Sanders Treatment of holocrine gland dysfunction with clostridia neurotoxins
US20040115222A1 (en) * 2002-09-06 2004-06-17 Michael Kane Method for reduction of wrinkles
DE50313304D1 (de) * 2002-09-10 2011-01-20 Siemens Ag Verfahren zur Kontrolle von Übertragungsressourcen eines paketorientierten Kommunikationsnetzes bei Topologieänderungen
US7422753B2 (en) * 2003-04-25 2008-09-09 Allergan, Inc. Methods for treating trichotillomania
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US20050042775A1 (en) * 2003-08-21 2005-02-24 Nicholas Pomato Botulinum antitoxin compositions and methods
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US20050144029A1 (en) * 2003-12-31 2005-06-30 Rakowski Richard R. Systems and methods for aesthetic improvement
US7270826B2 (en) * 2004-01-05 2007-09-18 Borodic Gary E Methods of using Botulinum toxin for the treatment of hypervolemic lip deformity (lip ectropion)
US9078892B2 (en) * 2004-02-26 2015-07-14 Allergan, Inc. Methods for treating pain and for treating a medication overuse disorder
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
BRPI0513850A (pt) * 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
AU2005288758A1 (en) * 2004-09-27 2006-04-06 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins for use in tissue healing
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
GB0426394D0 (en) * 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
PL1830872T3 (pl) * 2004-12-01 2011-09-30 Sec Dep For Health Białka fuzyjne
FR2879462B1 (fr) * 2004-12-21 2008-12-26 Sod Conseils Rech Applic Utilisation de toxine botulique pour une insensibilisation locale prolongee
US20080220021A1 (en) * 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
CA2597244A1 (en) * 2005-03-03 2006-09-14 Universite Catholique De Louvain Methods and compositions for the treatment of cancer
US20060269574A1 (en) * 2005-05-31 2006-11-30 De Beer Johann F Method of repairing tendons by surgery
US8105611B2 (en) * 2005-06-17 2012-01-31 Allergan, Inc. Treatment of autoimmune disorder with a neurotoxin
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
EP2015773A4 (en) * 2006-04-27 2010-05-05 Anterios Inc EXAMINATION OF THE EFFECTS OF TOPICAL ADMINISTRATION OF CHEMICALLY DENOMINATING PHARMACEUTICALS
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
EP1985276A1 (en) * 2007-04-26 2008-10-29 Merz Pharma GmbH & Co. KGaA Treatment of movement disorders by a combined use of a chemodenervating agent and automated movement therapy
CA2686642A1 (en) * 2007-06-01 2008-12-04 Merz Pharma Gmbh & Co. Kgaa Process for providing a temperature - stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin
US8586081B2 (en) * 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
US9038912B2 (en) * 2007-12-18 2015-05-26 Microsoft Technology Licensing, Llc Trade card services
EP2337790B1 (en) * 2008-08-29 2016-07-13 Merz Pharma GmbH & Co. KGaA Clostridial neurotoxins with altered persistency
JP5795539B2 (ja) * 2009-02-19 2015-10-14 メルツ ファルマ ゲーエムベーハー ウント コンパニー カーゲーアーアー 高純度の神経毒素を製造するための手段および方法
BRPI1014253A2 (pt) * 2009-07-02 2016-04-12 Merz Pharma Gmbh & Co Kgaa polinucleotídeo codificado um polipeptídeo de neurotoxina, vetor, célula hospedeira, anticorpo, uso de um polinucleotídeo, método para a fabricação de um polipeptídeo de neurotoxina e método para a fabricação de um medicamento
SI2526200T1 (sl) * 2010-01-22 2016-07-29 Merz Pharma Gmbh & Co. Kgaa In vitro preizkus za kvanitificiranje aktivnosti klostridijskega nevrotoksina
EP2776454A1 (en) * 2011-11-09 2014-09-17 Merz Pharma GmbH & Co. KGaA Modified neurotoxins with poly-glycine and uses thereof
KR102272580B1 (ko) * 2013-07-30 2021-07-05 메르츠 파마 게엠베하 운트 코. 카가아 보툴리눔 독소의 고순도 신경독성 성분의 제조 방법 및 이의 용도

Also Published As

Publication number Publication date
CL2007001911A1 (es) 2008-03-14
US20150290303A1 (en) 2015-10-15
WO2008000490A1 (en) 2008-01-03
CA2654214C (en) 2023-07-04
JP2009541396A (ja) 2009-11-26
US20080003241A1 (en) 2008-01-03
RU2009102848A (ru) 2010-08-10
JP5897784B2 (ja) 2016-03-30
KR20140142377A (ko) 2014-12-11
TWI519310B (zh) 2016-02-01
CA2654214A1 (en) 2008-01-03
EP2484373A1 (en) 2012-08-08
AU2007264008B2 (en) 2012-06-28
CN101460190A (zh) 2009-06-17
US20140010803A1 (en) 2014-01-09
US9095523B2 (en) 2015-08-04
US8557255B2 (en) 2013-10-15
EP2032157A1 (en) 2009-03-11
AU2007264008A1 (en) 2008-01-03
TW200819140A (en) 2008-05-01
JP2014015476A (ja) 2014-01-30
KR20090027732A (ko) 2009-03-17
IL195201A0 (en) 2009-08-03
RU2453333C2 (ru) 2012-06-20
BRPI0713061A2 (pt) 2012-04-10
US9572871B2 (en) 2017-02-21
KR20150126979A (ko) 2015-11-13
AR061669A1 (es) 2008-09-10
MX2009000253A (es) 2009-01-22
ZA200808491B (en) 2009-11-25
IL195201A (en) 2015-11-30

Similar Documents

Publication Publication Date Title
UY30450A1 (es) Aplicacinn de alta frecuencia de terapia con toxina botulenica
BR112014009785A8 (pt) método para tratar ou reduzir efp
WO2015054619A3 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
CO6260078A2 (es) Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros
MX2010003095A (es) Antidotos para inhibidores del factor xa y metodos para usar los mismos.
BR112013027119A2 (pt) novos conjugados ligante-droga (adcs) e uso dos mesmos
BR112014030966A2 (pt) composto, composição farmacêutica, e, métodos para inibir serina protease, para inibir tripsina e enteropeptidase, para tratar hiperglicemia, para profilaxia ou tratamento da diabetes, para melhorar a sensibilidade à insulina e para profilaxia ou tratamento da obesidade, hiperlipidemia, uma complicação diabética ou síndrome metabólica
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
BR112015009948A8 (pt) Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios
MX380767B (es) Métodos para reducir el riesgo cardiovascular.
AR055038A1 (es) Metodo y compuesto para tratar enfermedades vasculares perifericas
CL2011000553A1 (es) Metodo de tratamiento de esclerosis multiple progresiva, que comprende administrar un anticuerpo anti-cd20 a un paciente con edad inferior a 55 años y/o con lesiones que tiñen con gadolinio y/o con al menos un aumento de 1 punto edss y/o con un puntaje msss superior a 5 puntos; metodo de diagnostico; y articulo manufacturado.
BRPI0720588B8 (pt) derivados de pirazol-quinazolina substituídos, processo para sua preparação e seu uso como inibidores da quinase
NZ603717A (en) Suture line administration technique using botulinum toxins
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
WO2010101627A3 (en) Methods and systems for treatment and/or diagnosis
BR112013027554A2 (pt) "usos de compostos no tratamento de mal de alzheimer, doença de huntington, autismo e outros distúrbios"
BRPI0417493B8 (pt) uso de uma toxina botulínica para tratamento de distúrbios da pele
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
BR112016000658A2 (pt) pancreatina de alta atividade, processo para a preparação de pancreatina de aa tendo atividade lipásica específica de pelo menos aproximadamente 120 usp iu/mg e método de tratamento de um paciente sujeito a uma condição patológica associada com a insuficiência enzimática pandreática
BR112022007721A2 (pt) Método para o tratamento da demência
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
WO2015023553A3 (en) Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules
MX2021006548A (es) Proteina de neurofilamento para guiar la intervencion terapeutica en la esclerosis lateral amiotrofica.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170720